Scholarlink

Background <p>The treatment of Cutaneous Squamous Cell Carcinoma (CSCC) has undergone significant changes with the introduction of Immune Checkpoint Inhibitors (ICIs). While promising results have been observed, their efficacy remains limited to a subset of patients. Soluble immune checkpoint molecules, Interferon-gamma (IFN-γ), and cell-free DNA (cfDNA) could serve as potential biomarkers, particularly in ICI-based therapies.</p> Methods <p>In this study, we assessed the prognostic role of serum PD-L1, LAG-3, TIM-3, CTLA-4, IFN-γ, and plasma cfDNA in a cohort of 41 advanced (locally-advanced or metastatic) CSCC patients treated with the anti-PD-1 inhibitor cemiplimab.</p> Results <p>Our findings indicate that elevated baseline serum levels of IFN-γ are significantly associated with poorer treatment response and shorter Progression-Free Survival (PFS) in patients receiving cemiplimab. Moreover, patients with worse outcomes in terms of response and PFS exhibited a post-treatment decrease in IFN-γ levels. Higher baseline levels of plasma cfDNA and serum CTLA-4 demonstrated a trend toward association with unfavourable clinical outcomes.</p> Conclusions <p>These results highlight the potential of baseline and post-treatment IFN-γ levels as significant prognostic indicators for advanced CSCC patients undergoing cemiplimab therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月27日

查看全文
  • I. Vanni,
  • M. Croce,
  • L. Pastorino,
  • E. Allavena,
  • F. Barbero,
  • S. Coco,
  • S. Santamaria,
  • A. G. Bosio,
  • A. Boutros,
  • A. Rosa,
  • V. Fontana,
  • F. Spagnolo,
  • P. Ghiorzo,
  • E. T. Tanda

摘要

Background

The treatment of Cutaneous Squamous Cell Carcinoma (CSCC) has undergone significant changes with the introduction of Immune Checkpoint Inhibitors (ICIs). While promising results have been observed, their efficacy remains limited to a subset of patients. Soluble immune checkpoint molecules, Interferon-gamma (IFN-γ), and cell-free DNA (cfDNA) could serve as potential biomarkers, particularly in ICI-based therapies.

Methods

In this study, we assessed the prognostic role of serum PD-L1, LAG-3, TIM-3, CTLA-4, IFN-γ, and plasma cfDNA in a cohort of 41 advanced (locally-advanced or metastatic) CSCC patients treated with the anti-PD-1 inhibitor cemiplimab.

Results

Our findings indicate that elevated baseline serum levels of IFN-γ are significantly associated with poorer treatment response and shorter Progression-Free Survival (PFS) in patients receiving cemiplimab. Moreover, patients with worse outcomes in terms of response and PFS exhibited a post-treatment decrease in IFN-γ levels. Higher baseline levels of plasma cfDNA and serum CTLA-4 demonstrated a trend toward association with unfavourable clinical outcomes.

Conclusions

These results highlight the potential of baseline and post-treatment IFN-γ levels as significant prognostic indicators for advanced CSCC patients undergoing cemiplimab therapy.